Neoleukin Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NLTX research report →
About the company
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines.
- CEO
- Donna M. Cochener-Metcalfe
- IPO
- 2014
- Employees
- 7
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $8.20M
- P/E
- -11.26
- P/S
- 0.00
- P/B
- 0.33
- EV/EBITDA
- 2.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.88%
- ROIC
- -44.78%
- Revenue
- $0 · 0.00%
- Net Income
- $-90,351,000 · -20.24%
- EPS
- $0.00 · 100.00%
- Op Income
- $-103,328,000
- FCF YoY
- -9.73%
- 52W High
- $18.80
- 52W Low
- $3.42
- 50D MA
- $13.83
- 200D MA
- $14.98
- Beta
- 1.10
- Avg Volume
- 5.52K
Get TickerSpark's AI analysis on NLTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 16, 24 | Woods Robert Keith | other | 15,400 |
| Jan 16, 24 | PALEKAR ROHAN | other | 15,400 |
| Jan 16, 24 | Noonberg Sarah B. | other | 15,400 |
| Jan 16, 24 | Freedland Cory S. | other | 15,400 |
| Jan 16, 24 | BAFFI ROBERT | other | 15,400 |
| Jan 16, 24 | Jordan Julie | other | 75,000 |
| Jan 16, 24 | Jordan Julie | other | 0 |
| Dec 18, 23 | Cvijic Christine Mikail | other | 0 |
| Dec 18, 23 | Cvijic Christine Mikail | other | 37,800 |
| Dec 18, 23 | Cvijic Christine Mikail | other | 29,453 |
Our NLTX coverage
Recent articles, reports, and earnings notes.
No research on NLTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NLTX report →Similar companies
Peers in the same neighborhood.